Immuron Limited · ASX:IMC
Immuron — Investor Presentation (October 2022)
8 slides from Immuron's investor presentation, Oct 27, 2022
Slide 1: Investor Presentation
INVESTOR PRESENTATION 27 OCTOBER, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressio
Slide 3: Executive Summary
EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company • Two commercially available oral immunotherapeutic products – Travelan® and
Slide 4: Status of Product Portfolio and Key Milestones
STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES • The business is completing an assessment of the entire product Immuron’s Clinical Programs portfolio, target markets, competitive advantage and, key growth drivers Compound or Indication Phase Phase Phase Market brand name I II III • US Department of
Slide 5: Immuron's Clinical Programs – Opportunity Assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Lumanity* Opportunity Assessment for IMM-124E Lumanity Opportunity Assessment for IMM-529 • Immuron’s development of IMM-124E (hyperimmune bovine • Infectious disease experts reacted favorably to the IMM-529 MOA, and colostrum) as a prescription m
Slide 6: Addressable Market & Industry Overview
ADDRESSABLE MARKET & INDUSTRY OVERVIEW Immuron’s products are a subset of the global digestive health market, which a multi-billion-dollar market* ~$15b+ Billion Dollar Market Ateria strategic investment establishes Immuron’s position in the large and growing IBS market which is complementary to Tra
Slide 7: Thank You
THANK YOU 7
Slide 8: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: to 90% of volunteers 10.3109/00365521.2011.574726 Travelan as a broad Spectrum anti-bacterial I